Troponins and acute coronary syndrome by Rensburg, Megan & Path, F. C.
261  CME  July  2012  Vol. 30  No. 7
More about...
112 mono-components from more than 50 
allergen sources. Nanotechnology benefits 
paediatric diagnosis, because it requires very 
little blood to do a comprehensive allergen 
profile. It is mainly indicated for patients 
with multiple food and inhalant allergies. 
Its main drawbacks are onerous validation 
procedures and the risk of overdiagnosis; 
it requires specialist knowledge to prevent 
misinterpretation of the complex results of 
these tests.7 
Ongoing research is required to improve 
the ability of laboratory tests to assess 
the presence and severity of food allergy 
and to predict prognosis and resolution of 
disease.
Summary (Fig. 4)
•	 Commence investigation of food allergy 
with a detailed allergy-focused medical 
history and examination.
•	 Select the appropriate allergens and co-
allergens for sIgE or SPTs to confirm or 
exclude IgE-mediated allergy.
•	 Confirm equivocal findings with an OFC 
test.
•	 Monitor development of tolerance with 
sIgE (in children) and confirm with an 
OFC test.
•	 Allergy tests should only be undertaken 
by healthcare professionals who are 
competent to perform and interpret 
them.
•	 SPTs and OFC tests should only be 
undertaken where there are facilities to 
deal with an anaphylactic reaction.
•	 CRDs employing recombinant allergens 
and comprehensive allergen profiles 
using microarray nanotechnology offer 
complementary diagnostic tools for the 
allergy specialist.
Further reading and references available at www.
cmej.org.za
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Cardiac muscle injury is defined as the 
disruption of normal cardiac myocyte 
membrane integrity resulting in the loss of 
intracellular constituents such as troponin, 
creatine kinase, and myoglobin into the 
extracellular space. The mechanism of 
injury includes trauma, toxins and viral 
infections, but ischaemia or infarction – due 
to an imbalance between the supply and 
demand of oxygen – is the most common 
cause.1
Acute coronary syndrome (ACS) constitutes 
a large spectrum of clinical conditions, 
ranging from unstable angina pectoris to 
acute myocardial infarction (AMI). 
Diagnosis of acute myocardial 
infarction 
The diagnosis of AMI was traditionally 
made using the combination of chest pain, 
electrocardiographic (ECG) manifestations, 
and elevations in serum or plasma of cardiac 
biomarkers. The biomarkers tradionally 
requested are troponins and creatine kinase 
– MB fraction (CK-MB). Clinical symptoms 
such as chest pain are frequently atypical or 
absent, and ECG changes may be nonspecific 
or absent. This has resulted in the diagnosis 
of AMI becoming more dependent on the 
measurement of biomarkers.
Because of their greater sensitivity and 
specificity,1 cardiac troponins (cTn) are the 
biomarkers of choice for the evaluation 
and management of patients with ACS, 
and in the diagnosis of AMI. Guidelines 
set in 2007 by the National Academy of 
Clinical Biochemistry and the European 
Society of Cardiology/American College 
of Cardiology stated that ‘in the presence 
of a clinical history suggestive of ACS, 
the following is considered indicative 
of myocardial necrosis consistent with 
myocardial infarction: an elevation in cTn 
concentrations above the 99th percentile of 
a healthy population, accompanied by an 
assay imprecision of ≤ 10% …’.2,3 In addition, 
a rising and/or falling troponin pattern is 
an important component of the universal 
definition of AMI.3
Troponin biochemistry
Cardiac troponins consist of three proteins 
known as cTnC, cTnI and cTnT based on 
their function: C for calcium-binding, I 
for inhibition of actin-myosin interactions, 
and T for tropomyosin binding to facilitate 
contraction.2,3 cTn is released in the setting 
of irreversible damage to the myocyte and 
starts rising in blood 4 - 6 hours after cell 
death, peaks at approximately 18 - 24 hours 
and remains detectable for up to 14 days. 
This time frame is observed when using 
non-high-sensitivity cTn assays.1
‘Highly sensitive’ cTn
The ever-increasing sensitivity of cTn 
assays has led to the development of 
‘highly sensitive’ cTn (hsTn) assays, capable 
of measuring cTn levels below the 99th 
percentile in a healthy population. Use of 
these hsTn assays makes it possible to detect 
low levels of cTn even in healthy subjects.4 
A rise in cTn can be observed 2 - 3 hours 
after the onset of an AMI, leading to earlier 
diagnosis and therapeutic intervention.1 
Serial changes documented by a second 
measurement will help to differentiate acute 
cardiac disorders (showing a rise and/or 
fall) from chronic cardiac disease, which 
will usually exhibit constant cTn levels.5 The 
improved sensitivity involves sacrificing 
reduced specificity, leading to additional 
diagnostic challenges for clinicians.6  With 
the increased use of hsTn assays and the 
application of the 99th  percentile as the 
decision limit for AMI, a substantial increase 
in detection of patients with elevated 
cTn levels will be observed, and a high 
percentage of patients will be misclassified. 
It should be emphasised that AMI is not 
the only cause of myocyte necrosis, and 
therefore non-ischaemic causes of troponin 
elevation should be kept in mind.3 The high 
262  CME  July  2012  Vol. 30  No. 7
More about...
sensitivity of cTn, even in the presence of 
minimal cardiac myocyte necrosis, means 
that these markers may become ‘positive’ 
even in the absence of thrombotic ACS. 
Below is a list of causes of elevated cTn in 
the absence of ACS. 
Causes of elevated cTn other than 
ACS1
•	 Cardiac causes
•   cardiac contusion (trauma)
•   cardiac surgery
•   cardioversion
•   endomyocardial biopsy
•   acute and chronic heart failure
•   aortic dissection
•   aortic valve disease
•   hypertrophic cardiomyopathy
•   myocarditis
•   endocarditis
•   coronary vasospasm
•   post-cardiac transplantation
•    post-percutaneous coronary 
inter-vention
•   tachyarrhythmia
•   bradyarrythmia
•    rhabdomyolysis with myocyte  
necrosis.
•	 Non-cardiac causes
•   critically ill patients
•   pulmonary embolism
•   severe pulmonary hypertension
•   renal failure
•   stroke
•   subarachnoid haemorrhage
•   cardiotoxic drugs, e.g. amiodarone
•   sepsis
•   extensive burns
•   extreme exertion
•   infiltrative disease, e.g. amyloidosis.
•	 False-positive
•   heterophilic antibodies
•   rheumatoid factors
•   fibrin clots
•   microparticles
•   analyser malfunction.
Ongoing research is in the process of best 
defining algorithms on how to interpret data 
from hsTn assays in clinical practice. These 
include development of rule-out and rule-in 
algorithms as well as optimising the timing 
of the second measurement.5 
Potential uses for hsTn
•	 Earlier diagnosis of patient with ACS, 
especially AMI.
•	 Risk stratification of patients with stable 
coronary artery disease; the higher the 
hsTn level, the higher the incidence of 
cardiovascular events.5
•	 Detection of non-ischaemic causes of 
elevated cTn.
Summary
•	 Correlate biochemical marker levels with 
the clinical scenario (e.g. chest pain, ECG).
•	 Observe cTn kinetics – a rise and/or fall 
in levels.
•	 Take note of the non-ischaemic causes of 
elevated cTn levels.
•	 hsTn can be a useful cardiac biomarker.
References available at www.cmej.org.za
SINGLE SUTURE
3D blood vessels could aid artificial organs
Growing artificial organs might help solve the transplantation shortage, but one major hurdle still exists: it is difficult to get blood vessels to 
grow all the way through a large organ. A gel that allows blood vessels to grow in precise shapes and respond to human cells in a manner similar 
to natural vessels might help jumpstart that process.
Ying Zheng and colleagues at the University of Washington in Seattle injected human endothelial cells – which line blood vessels – into tiny 
channels within a collagen gel.
The endothelial cells spread throughout the channels, which were only micrometres in width, and formed hollow, three-dimensional tubes, 
or microvessels. When the researchers pumped blood into the system, it moved through the microvessels without sticking. It could even flow 
smoothly around 90 degree bends.
The researchers then added a series of proteins involved in inflammation. They found that the proteins caused the blood to clot inside the 
microvessels, just as it would in the body. Because the system reacted to these stimuli in the same way as a natural vascular system would, Zheng 
says, it might one day be useful for screening drugs.
When the group injected human brain and muscle cells into the gel, along with proteins that stimulate blood vessel growth, the microvessels 
showed that they could branch and integrate with the two types of tissue.
Because the channels can be directed into any shape, bioengineer Linda Griffith of Massachusetts Institute of Technology is hopeful that the 
system can model complex vascular systems such as the blood-brain barrier, which is difficult to study in living animals. Additionally, she adds, 
researchers could study how cancers metastasise by putting other cell types, such as bone or liver cells, into the channels along with cancerous 
cells.
Zheng says that the next step is to use the system as a starting point for an artificial organ. Drawing the channels in the right shape will allow 
the organ to have an adequate blood supply throughout.
Journal reference: Proceedings of the National Academy of Sciences, doi: 10.1073/pnas.1201240109
New Scientist, 28 May 2012.
